Drug intelligence / Profile preview

escherichia coli strain 83972

Development stage: Phase 1
Lead developer: Region Skåne
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Intravesical

Overview

Escherichia coli strain 83972 is a non-pathogenic, probiotic strain of *E. coli* being investigated as a live biotherapeutic product for the prevention of recurrent urinary tract infections (UTIs). [2, 5] Originally isolated from a girl with long-term asymptomatic bacteriuria, this strain is well-adapted to colonize the human bladder without causing symptoms. [2, 10] The therapeutic approach, known as bacterial interference, involves intentionally colonizing the patient's bladder with this harmless bacterial strain via intravesical instillation. [1, 2, 24] This induced state of asymptomatic bacteriuria is intended to prevent the colonization and growth of pathogenic bacteria by outcompeting them for nutrients and attachment sites, thereby reducing the frequency of symptomatic UTIs. [1, 2] Clinical studies have demonstrated its safety and suggested efficacy in patients prone to recurrent infections, including those with neurogenic bladders and incomplete bladder emptying. [3, 9, 18]

Other names: ABU E. coli 83972

Targets

FimH (Type 1 fimbrial adhesin)

Beyond the preview

Go deeper on escherichia coli strain 83972.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on escherichia coli strain 83972.

Explore the full profile